_for_Treating_Psoriasis_An_Investigator_Initiated_Open_Label_Study_Figure2)
follow-up and one withdrew due to perceived lack of efficacy. HAT1 was well tolerated and patients reported no treatmentrelated adverse events. There were no statistically significant differences in all examined parameters between groups treated with HAT1 monotherapy versus with concomitant systemic therapy. Therefore, the data was pooled between these two groups. Modified ITT analysis showed a significant reduction of sPGAxBSA by 58.7% (95% confidence interval (CI) [40.1, 77.4]) by week 12 (Figure 1A). Significant mean percentage improvement of sPGAxBSA was also noted as early as week 4 by 40.9% (95% CI [23.2, 58.6]). Percentage improvement from baseline for DLQI was 41.3% (95% CI [17.0, 65.6]) (Figure 1E). Furthermore, significant percent improvement at week 12 from baseline were observed for BSA, PASI, sPGA, and NRS (Figure 1B, 1C, 1D, and 1F).
This study is limited by the absence of a vehicle-controlled arm and its small number of patients. The addition of patients on systemic medications may also confound the results of the study. The results would benefit from a larger cohort and longer study duration to assess for long term efficacy and adverse effects.
Topical application of HAT1 for 12 weeks showed significant reduction in disease burden and symptom relief in mild psoriasis as evidenced by improvements in sPGAxBSA as well as the DLQI and NRS. This well-tolerated herbal formulation can provide an alternative over-the-counter regimen, especially in those seeking botanical products.
DISCLOSURES
Boni Elewski, MD is an investigator for AbbVie, Anaptys- Bio, Boehringer Ingelheim, Bristol Myers Squibb, Amgen (previously Celgene), Incyte, Leo, Eli Lilly, Merck, Novartis, Pfizer, Regeneron, Sun, Valeant (Ortho dermatology), and Vanda. Boni Elewski is a consultant for Boehringer Ingelheim, BMS, Amgen (previously Celgene), Leo, Lilly, Menlo, Novartis, Valeant (Ortho dermatology), and Verrica. Other authors do not have conflicts to declare.
Funding sources: Procter & Gamble
Funding sources: Procter & Gamble
REFERENCES
1. Mills KJ, Sherrill JD, Matheny H, et al. 765 Anti-inflammatory properties of a unique mixture of botanical extracts in in vitro models of psoriatic inflammation. J Invest Dermatol. 2018;138(5):S130.
2. Alex P, Williams S, Sutton L, et al. Efficacy and safety of HAT1 compared with calcipotriol in the treatment of patients with mild to moderate chronic plaque psoriasis: results from an open-label randomized comparative pilot clinical study. Clin Exp Dermatol. 2020 Apr;45(3):318-322.
3. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931-937.
2. Alex P, Williams S, Sutton L, et al. Efficacy and safety of HAT1 compared with calcipotriol in the treatment of patients with mild to moderate chronic plaque psoriasis: results from an open-label randomized comparative pilot clinical study. Clin Exp Dermatol. 2020 Apr;45(3):318-322.
3. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931-937.
AUTHOR CORRESPONDENCE
Allen S.W. Oak MD siwon.oak@gmail.com
